Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 23;31(8):4141-4157.
doi: 10.3390/curroncol31080309.

New Insight for Axillary De-Escalation in Breast Cancer Surgery: "SoFT Study" Retrospective Analysis

Gianluca Vanni  1 , Marco Materazzo  1   2 , Floriana Paduano  1 , Marco Pellicciaro  1   2 , Giordana Di Mauro  3 , Enrica Toscano  3 , Federico Tacconi  4 , Benedetto Longo  1   5 , Valerio Cervelli  5 , Massimiliano Berretta  6 , Oreste Claudio Buonomo  1   7
Affiliations

New Insight for Axillary De-Escalation in Breast Cancer Surgery: "SoFT Study" Retrospective Analysis

Gianluca Vanni et al. Curr Oncol. .

Abstract

Background: The SOUND study demonstrated that an axillary de-escalation may be sufficient in locoregional and distant disease control in selected early breast cancer (EBC) patients. To establish any preoperative variables that may drive sentinel lymph node biopsy (SLNB) omission, a study named sentinel omission risk factor (SOFT) 1.23 was planned. Methods: A single-center retrospective study from a prospectively maintained database was designed, aiming at underlying preoperative prognostic factors involved in sentinel lymph node (SLN) metastasis (lymph node involvement (LN+) vs. negative lymph node (LN-) group). Secondary outcomes included surgical room occupancy analysis for SLNB in patients fulfilling the SOUND study inclusion criteria. The institutional ethical committee Area Territoriale Lazio 2 approved the study (n° 122/23). Results: Between 1 January 2022 and 30 June 2023, 160 patients were included in the study and 26 (%) were included in the LN+ group. Multifocality, higher cT stage, and larger tumor diameter were reported in the LN+ group (p = 0.020, p = 0.014, and 0.016, respectively). Tumor biology, including estrogen and progesterone receptors, and molecular subtypes showed association with the LN+ group (p < 0.001; p = 0.001; and p = 0.001, respectively). A total of 117 (73.6%) patients were eligible for the SOUND study and the potential operating room time saved was 2696.81 min. Conclusions: De-escalating strategies may rationalize healthcare activities. Multifactorial risk stratification may further refine the selection of patients who could benefit from SLNB omission.

Keywords: axillary surgery; breast neoplasm; early breast cancer; sentinel lymph node biopsy; surgical de-escalation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study flowchart. BC: breast cancer; ALND: axillary lymph node dissection; SLNB: sentinel lymph node biopsy.
See this image and copyright information in PMC

References

    1. Veronesi U., Viale G., Paganelli G., Zurrida S., Luini A., Galimberti V., Veronesi P., Intra M., Maisonneuve P., Zucca F., et al. Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results: Of a Randomized Controlled Study. Ann. Surg. 2010;251:595–600. doi: 10.1097/SLA.0b013e3181c0e92a. - DOI - PubMed
    1. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Ashikaga T., Weaver D.L., Miller B.J., Jalovec L.M., Frazier T.G., et al. Technical Outcomes of Sentinel-Lymph-Node Resection and Conventional Axillary-Lymph-Node Dissection in Patients with Clinically Node-Negative Breast Cancer: Results from the NSABP B-32 Randomised Phase III Trial. Lancet Oncol. 2007;8:881–888. doi: 10.1016/S1470-2045(07)70278-4. - DOI - PubMed
    1. Giuliano A.E., Ballman K.V., McCall L., Beitsch P.D., Brennan M.B., Kelemen P.R., Ollila D.W., Hansen N.M., Whitworth P.W., Blumencranz P.W., et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA—J. Am. Med. Assoc. 2017;318:918–926. doi: 10.1001/jama.2017.11470. - DOI - PMC - PubMed
    1. Tinterri C., Gentile D., Gatzemeier W., Sagona A., Barbieri E., Testori A., Errico V., Bottini A., Marrazzo E., Dani C., et al. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. Ann. Surg. Oncol. 2022;29:5732–5744. doi: 10.1245/s10434-022-11866-w. - DOI - PubMed
    1. Galimberti V., Cole B.F., Viale G., Veronesi P., Vicini E., Intra M., Mazzarol G., Massarut S., Zgajnar J., Taffurelli M., et al. Axillary Dissection versus No Axillary Dissection in Patients with Breast Cancer and Sentinel-Node Micrometastases (IBCSG 23-01): 10-Year Follow-up of a Randomised, Controlled Phase 3 Trial. Lancet Oncol. 2018;19:1385–1393. doi: 10.1016/S1470-2045(18)30380-2. - DOI - PubMed

LinkOut - more resources